| Support for Korean Companies' Global Expansion through Global Network Utilization in Clinical Trials and FDA Approvals
▲ From left to right: Jonghyun Park, Head of JNPMEDI Center; Jaehyun Lee, COS; Soohyun Yoo, CMO; Kwunho Jeong, CEO of JNPMEDI; Gregory Hill, Representative of the University of Utah Asia Campus; Jihoon Hyun, Deputy Director of Industry-Academia Cooperation; Yoonah Cho, Administrative Coordinator; Joonhyuk Lim, Global BD Lead of JNPMEDI
JNPMEDI has announced the signing of a Memorandum of Understanding (MOU) with the University of Utah Asia Campus to promote the pharmaceutical and biotechnology industries between South Korea and the United States. The announcement was made on the 4th, following the MOU signing ceremony held on June 25 at the University of Utah Asia Campus.
The ceremony was attended by key figures including JNPMEDI's CEO Kwunho Jeong and COS Jaehyun Lee, along with Gregory Hill, Representative of the University of Utah Asia Campus, and Jihoon Hyun, Deputy Director of the Industry-Academia Cooperation.
Under this agreement, both parties will leverage their global networks to actively support South Korean companies in conducting clinical trials and obtaining FDA approvals in the United States. They will also provide related education and act as facilitators.
Gregory Hill, Representative of the University of Utah Asia Campus, expressed his enthusiasm, stating, "Given that the University of Utah is home to the second largest bio hub in the U.S., we can effectively support the successful global expansion of Korean companies using our local network."
Kwunho Jeong, CEO of JNPMEDI, commented, "This agreement combines the expertise and resources of both institutions, providing domestic companies with opportunities to strengthen their competitiveness in the global market. This MOU will enhance access to the U.S. market and foster continuous technological exchange and cooperation between the two countries."
| Support for Korean Companies' Global Expansion through Global Network Utilization in Clinical Trials and FDA Approvals
▲ From left to right: Jonghyun Park, Head of JNPMEDI Center; Jaehyun Lee, COS; Soohyun Yoo, CMO; Kwunho Jeong, CEO of JNPMEDI; Gregory Hill, Representative of the University of Utah Asia Campus; Jihoon Hyun, Deputy Director of Industry-Academia Cooperation; Yoonah Cho, Administrative Coordinator; Joonhyuk Lim, Global BD Lead of JNPMEDI
JNPMEDI has announced the signing of a Memorandum of Understanding (MOU) with the University of Utah Asia Campus to promote the pharmaceutical and biotechnology industries between South Korea and the United States. The announcement was made on the 4th, following the MOU signing ceremony held on June 25 at the University of Utah Asia Campus.
The ceremony was attended by key figures including JNPMEDI's CEO Kwunho Jeong and COS Jaehyun Lee, along with Gregory Hill, Representative of the University of Utah Asia Campus, and Jihoon Hyun, Deputy Director of the Industry-Academia Cooperation.
Under this agreement, both parties will leverage their global networks to actively support South Korean companies in conducting clinical trials and obtaining FDA approvals in the United States. They will also provide related education and act as facilitators.
Gregory Hill, Representative of the University of Utah Asia Campus, expressed his enthusiasm, stating, "Given that the University of Utah is home to the second largest bio hub in the U.S., we can effectively support the successful global expansion of Korean companies using our local network."
Kwunho Jeong, CEO of JNPMEDI, commented, "This agreement combines the expertise and resources of both institutions, providing domestic companies with opportunities to strengthen their competitiveness in the global market. This MOU will enhance access to the U.S. market and foster continuous technological exchange and cooperation between the two countries."